NO20072344L - Trombineresptorantagonister. - Google Patents
Trombineresptorantagonister.Info
- Publication number
- NO20072344L NO20072344L NO20072344A NO20072344A NO20072344L NO 20072344 L NO20072344 L NO 20072344L NO 20072344 A NO20072344 A NO 20072344A NO 20072344 A NO20072344 A NO 20072344A NO 20072344 L NO20072344 L NO 20072344L
- Authority
- NO
- Norway
- Prior art keywords
- bond
- double bond
- compounds
- het
- arrhythmia
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 229940125692 cardiovascular agent Drugs 0.000 abstract 1
- 239000002327 cardiovascular agent Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000010235 heart cancer Diseases 0.000 abstract 1
- 208000024348 heart neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61751404P | 2004-10-08 | 2004-10-08 | |
| PCT/US2005/035745 WO2006041872A2 (fr) | 2004-10-08 | 2005-10-05 | Antagonistes des recepteurs de la thrombine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072344L true NO20072344L (no) | 2007-07-04 |
Family
ID=36061549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072344A NO20072344L (no) | 2004-10-08 | 2007-05-07 | Trombineresptorantagonister. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7488752B2 (fr) |
| EP (2) | EP1802609A2 (fr) |
| JP (1) | JP2008515899A (fr) |
| KR (1) | KR20070101216A (fr) |
| CN (1) | CN101072772A (fr) |
| AR (1) | AR054611A1 (fr) |
| AU (1) | AU2005294490A1 (fr) |
| BR (1) | BRPI0518159A (fr) |
| CA (1) | CA2582639A1 (fr) |
| EC (1) | ECSP077372A (fr) |
| IL (1) | IL182355A0 (fr) |
| MX (1) | MX2007004197A (fr) |
| NO (1) | NO20072344L (fr) |
| RU (1) | RU2408594C2 (fr) |
| TW (1) | TW200626584A (fr) |
| WO (1) | WO2006041872A2 (fr) |
| ZA (1) | ZA200702790B (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| TW200812619A (en) * | 2006-04-06 | 2008-03-16 | Schering Corp | TRA combination therapies |
| CN101541782A (zh) * | 2006-10-04 | 2009-09-23 | 先灵公司 | 作为凝血酶受体拮抗剂的二环和三环衍生物 |
| US8227412B2 (en) * | 2007-03-29 | 2012-07-24 | Tsopanoglou Nikos E | Bioactive parstatin peptides and methods of use |
| WO2008128038A2 (fr) * | 2007-04-13 | 2008-10-23 | The Scripps Research Institute | Procédés et compositions permettant de traiter les dysfonctionnements cardiaques |
| PL2558462T3 (pl) | 2010-04-16 | 2015-03-31 | Sanofi Sa | Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1 |
| ES2532902T3 (es) | 2010-04-16 | 2015-04-01 | Sanofi | Piridil-vinil-pirroles tricíclicos como inhibidores de PAR1 |
| WO2012149285A1 (fr) * | 2011-04-28 | 2012-11-01 | Claire Mitchell | Méthode de traitement d'une dégénérescence maculaire par la modulation des récepteurs p2y12 ou p2x7 |
| US9340530B2 (en) * | 2012-03-06 | 2016-05-17 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| EA027113B1 (ru) * | 2012-05-04 | 2017-06-30 | Новартис Аг | Регуляторы пути комплемента и их применение |
| US9475806B2 (en) | 2013-03-14 | 2016-10-25 | Novartis Ag | Complement factor B inhibitors and uses there of |
| WO2015026686A1 (fr) | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | Dérivés bicycliques de 3'-pyridyl substitué-6,6-difluoro himbacine |
| WO2015026693A1 (fr) | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | Dérivés bicycliques de 7a-amide substitué-6,6-difluoro himbacine |
| WO2015026685A1 (fr) | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | Dérivés bicycliques de 7a-hétérocycle substitué-6,6-difluoro himbacine |
| CN104447927A (zh) * | 2013-09-13 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 坎格雷洛一水合物晶体及其制备方法 |
| CN104447928A (zh) * | 2013-09-13 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 坎格雷洛二水化合物 |
| CN105849090A (zh) * | 2013-10-30 | 2016-08-10 | 诺华股份有限公司 | 2-苄基-苯并咪唑补体因子b抑制剂及其用途 |
| WO2016058144A1 (fr) * | 2014-10-15 | 2016-04-21 | Merck Sharp & Dohme Corp. | Préparation et utilisation de dérivés de sulfamides cycliques comme antagonistes des récepteurs par -1 |
| CN105732595B (zh) | 2015-12-22 | 2018-08-28 | 山东大学 | 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途 |
| CN107304199B (zh) * | 2016-04-22 | 2021-09-21 | 江苏天士力帝益药业有限公司 | 一种新的喜巴辛类似物及其在医药中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| KR100393492B1 (ko) * | 1997-11-25 | 2003-08-02 | 쉐링 코포레이션 | 트롬빈 수용체 길항제 |
| US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| ES2291323T3 (es) * | 2000-06-15 | 2008-03-01 | Schering Corporation | Antagonistas de receptores de trombina. |
| BR0213967A (pt) | 2001-10-18 | 2005-08-30 | Schering Corp | Análogos de himbacina como antagonistas do receptor de trombina |
| US7086034B2 (en) * | 2002-06-28 | 2006-08-01 | Canon Kabushiki Kaisha | Method, program, and storage medium for acquiring logs |
-
2005
- 2005-10-05 WO PCT/US2005/035745 patent/WO2006041872A2/fr not_active Ceased
- 2005-10-05 AU AU2005294490A patent/AU2005294490A1/en not_active Abandoned
- 2005-10-05 MX MX2007004197A patent/MX2007004197A/es active IP Right Grant
- 2005-10-05 US US11/243,708 patent/US7488752B2/en active Active
- 2005-10-05 EP EP05802841A patent/EP1802609A2/fr not_active Withdrawn
- 2005-10-05 EP EP09156735.4A patent/EP2075250B1/fr not_active Expired - Lifetime
- 2005-10-05 BR BRPI0518159-3A patent/BRPI0518159A/pt not_active IP Right Cessation
- 2005-10-05 CN CNA2005800422977A patent/CN101072772A/zh active Pending
- 2005-10-05 CA CA002582639A patent/CA2582639A1/fr not_active Abandoned
- 2005-10-05 RU RU2007116850/04A patent/RU2408594C2/ru not_active IP Right Cessation
- 2005-10-05 KR KR1020077007897A patent/KR20070101216A/ko not_active Ceased
- 2005-10-05 JP JP2007535765A patent/JP2008515899A/ja active Pending
- 2005-10-06 TW TW094135027A patent/TW200626584A/zh unknown
- 2005-10-06 AR ARP050104221A patent/AR054611A1/es not_active Application Discontinuation
-
2007
- 2007-04-01 IL IL182355A patent/IL182355A0/en unknown
- 2007-04-03 ZA ZA200702790A patent/ZA200702790B/xx unknown
- 2007-04-04 EC EC2007007372A patent/ECSP077372A/es unknown
- 2007-05-07 NO NO20072344A patent/NO20072344L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2075250A3 (fr) | 2009-10-14 |
| EP2075250A2 (fr) | 2009-07-01 |
| RU2408594C2 (ru) | 2011-01-10 |
| US7488752B2 (en) | 2009-02-10 |
| WO2006041872A2 (fr) | 2006-04-20 |
| JP2008515899A (ja) | 2008-05-15 |
| AU2005294490A1 (en) | 2006-04-20 |
| ECSP077372A (es) | 2007-05-30 |
| KR20070101216A (ko) | 2007-10-16 |
| ZA200702790B (en) | 2008-09-25 |
| CA2582639A1 (fr) | 2006-04-20 |
| CN101072772A (zh) | 2007-11-14 |
| MX2007004197A (es) | 2007-06-15 |
| AR054611A1 (es) | 2007-07-04 |
| IL182355A0 (en) | 2007-07-24 |
| TW200626584A (en) | 2006-08-01 |
| WO2006041872A3 (fr) | 2007-01-04 |
| BRPI0518159A (pt) | 2008-11-04 |
| EP2075250B1 (fr) | 2015-03-04 |
| RU2007116850A (ru) | 2008-11-20 |
| US20060079684A1 (en) | 2006-04-13 |
| EP1802609A2 (fr) | 2007-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072344L (no) | Trombineresptorantagonister. | |
| WO2008042422A3 (fr) | Dérivés bicycliques et tricycliques utilisés comme antagonistes du récepteur de la thrombine | |
| WO2007126771A3 (fr) | Dérivés d'himbacine monocycliques et bicycli ques utiles en tant qu'antagonistes du récepteur de la thrombine | |
| WO2006105217A3 (fr) | Antagonistes du recepteur de la thrombine spirocyclique | |
| MY139335A (en) | Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists | |
| NO20060665L (no) | N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer | |
| ATE478044T1 (de) | Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c | |
| NO20060664L (no) | N-substituerte benzimidazolyl C-kit inhibitorer | |
| NO20082389L (no) | 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler | |
| SE0402735D0 (sv) | Novel compounds | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| NO20051527L (no) | 3-(sulfonamidoetyl) -indol-derivater for anvendelse som glukocorticoid-mimetica ved behandling av inflammatoriske, allergiske og proliferative sykdommer. | |
| NO20071140L (no) | Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon | |
| SE0400284D0 (sv) | Novel compounds | |
| NO20070258L (no) | Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer | |
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| EA200900135A1 (ru) | Производные пиразола в качестве ингибиторов цитохрома р450 | |
| NO20060195L (no) | Kinolylamidderivater som CCR-5-antagonister | |
| NO20082077L (no) | Spirosykliske quinazolinderivater som PDE7-inhibitorer | |
| DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
| EA200701324A1 (ru) | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина | |
| NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
| MX2009003758A (es) | Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina. | |
| WO2007075809A3 (fr) | Derives d'oxazoloisoquinoléine en tant qu'antagonistes de recepteur de thrombine | |
| ATE499372T1 (de) | Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |